Venus Concept Receives FDA 510(k) Clearance of Venus BlissMAX
Venus Concept Inc announces it has received 510(k) clearance from the US Food and Drug Administration to market the Venus BlissMAX device in the United States.
Venus Concept Inc announces it has received 510(k) clearance from the US Food and Drug Administration to market the Venus BlissMAX device in the United States.
Incyte’s sNDA for ruxolitinib cream in children ages 2–11 now faces a new action date to allow additional data review.